Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 786

1.

Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.

Castle PE, Glass AG, Rush BB, Scott DR, Wentzensen N, Gage JC, Buckland J, Rydzak G, Lorincz AT, Wacholder S.

J Clin Oncol. 2012 Sep 1;30(25):3044-50. doi: 10.1200/JCO.2011.38.8389. Epub 2012 Jul 30.

2.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.

PMID:
21865084
3.

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M.

J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9.

PMID:
16030305
4.

Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3.

Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE.

Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1675-81. doi: 10.1158/1055-9965.EPI-10-0251.

5.

The role of human papillomavirus type 16/18 genotyping in predicting high-grade cervical/vaginal intraepithelial neoplasm in women with mildly abnormal Papanicolaou results.

Guo M, Gong Y, Wang J, Dawlett M, Patel S, Liu P, Bevers TB, Sneige N.

Cancer Cytopathol. 2013 Feb;121(2):79-85. doi: 10.1002/cncy.21240. Epub 2012 Dec 5.

6.

Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.

Dijkstra MG, van Zummeren M, Rozendaal L, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, Meijer CJ, Berkhof J.

BMJ. 2016 Oct 4;355:i4924. doi: 10.1136/bmj.i4924. Erratum in: BMJ. 2016 Oct 27;355:i5782.

7.

Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.

Kjær SK, Frederiksen K, Munk C, Iftner T.

J Natl Cancer Inst. 2010 Oct 6;102(19):1478-88. doi: 10.1093/jnci/djq356. Epub 2010 Sep 14.

8.

The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.

Gage JC, Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Behrens C, Sharma A, Zhao FH, Cuzick J, Yang ZH, Kinney WK.

Cancer Cytopathol. 2014 Nov;122(11):842-50. doi: 10.1002/cncy.21463. Epub 2014 Jul 9.

10.

Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California.

Castle PE, Shaber R, LaMere BJ, Kinney W, Fetterma B, Poitras N, Lorey T, Schiffman M, Dunne A, Ostolaza JM, McKinney S, Burk RD.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):946-53. doi: 10.1158/1055-9965.EPI-10-1267. Epub 2011 Mar 17.

11.

Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.

Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P.

Obstet Gynecol. 2007 Jun;109(6):1325-31.

PMID:
17540804
12.

Assessment of HPV DNA test value in management women with cytological findings of ASC-US, CIN1 and CIN2.

Pajtler M, Milicić-Juhas V, Milojković M, Topolovec Z, Curzik D, Mihaljević I.

Coll Antropol. 2010 Mar;34(1):81-6.

PMID:
20432737
13.

Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18.

Xi LF, Koutsky LA, Hildesheim A, Galloway DA, Wheeler CM, Winer RL, Ho J, Kiviat NB.

Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):4-10.

14.

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.

J Natl Cancer Inst. 2003 Jan 1;95(1):46-52.

PMID:
12509400
15.

Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.

Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LC, Cuzick J, Myers O, Castle PE, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):36-42. doi: 10.1158/1055-9965.EPI-15-0669. Epub 2015 Oct 30.

16.

The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.

Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Robertson M, Castle PE; New Mexico HPV Pap Registry Steering Committee.

Int J Cancer. 2014 Aug 1;135(3):624-34. doi: 10.1002/ijc.28605. Epub 2014 Apr 15.

17.

Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study.

Sánchez-Lander J, Cortiñas P, Loureiro CL, Pujol FH, Medina F, Capote-Negrín L, Bianchi G, García-Barriola V, Ruiz-Benni A, Avilán-Rovira J, Acosta H.

Cancer Epidemiol. 2012 Oct;36(5):e284-7. doi: 10.1016/j.canep.2012.04.005. Epub 2012 May 17.

PMID:
22608058
18.

A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study.

Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, Buckland J, Sherman ME, Rydzak G, Kirk P, Lorincz AT, Wacholder S, Burk RD.

Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1398-409. doi: 10.1158/1055-9965.EPI-11-0206. Epub 2011 May 20. Erratum in: Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1390-1.

19.

Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.

Guo M, Khanna A, Wang J, Dawlett MA, Kologinczak TL, Lyons GR, Bassett RL Jr, Sneige N, Gong Y, Bevers TB.

Cancer Cytopathol. 2017 Aug;125(8):644-651. doi: 10.1002/cncy.21877. Epub 2017 May 12.

PMID:
28498639
20.

Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial.

Monsonego J, Cox JT, Behrens C, Sandri M, Franco EL, Yap PS, Huh W.

Gynecol Oncol. 2015 Apr;137(1):47-54. doi: 10.1016/j.ygyno.2015.01.551. Epub 2015 Feb 8.

PMID:
25667973

Supplemental Content

Support Center